Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - SALIX PHARMACEUTICALS LTD | d251996d8k.htm |
| EX-99.3 - PRESS RELEASE DATED NOVEMBER 4, 2011 - SALIX PHARMACEUTICALS LTD | d251996dex993.htm |
| EX-99.1 - PRESS RELEASE DATED NOVEMBER 8, 2011 - SALIX PHARMACEUTICALS LTD | d251996dex991.htm |
Exhibit 99.2
FOR IMMEDIATE RELEASE
| Contact: | Adam C. Derbyshire | G. Michael Freeman | ||
| Executive Vice President | Associate Vice President, Investor Relations | |||
| and Chief Financial Officer | and Corporate Communications | |||
| 919-862-1000 | 919-862-1000 |
Salix Pharmaceuticals to Present at
Two Investment Conferences in November
RALEIGH, NC, November 3, 2011 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at two health care investment conferences during November 2011. Information regarding these conferences is provided below:
Credit Suisse 2011 Healthcare Conference
Phoenix, AZ Thursday, Nov. 10 11:30 a.m. ET
23rd Annual Piper Jaffray Health Care Conference
New York, NY Tuesday, Nov. 29 11:30 a.m. ET
Interested parties can access a live audio web cast of these presentations at http://www.salix.com. A replay of the presentations will be available at the same location.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company’s gastroenterology specialty sales and marketing team.
Salix trades on the NASDAQ Global Select Market under the ticker symbol “SLXP”.
For more information, please visit our Website at www.salix.com or contact the Company at 919-862-1000. Follow us on Twitter (@SalixPharma) and Facebook (www.facebook.com/SalixPharma). Information on our web site is not incorporated in our SEC filings.